Ye Zhang1, Rong Ren1, Larry D Sanford2, Linghui Yang1, Yuenan Ni1, Junying Zhou1, Jihui Zhang3, Yun-Kwok Wing3, Jie Shi4, Lin Lu4, Xiangdong Tang5. 1. Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Mental Health Center, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. 2. Sleep Research Laboratory, Department of Pathology and Anatomy, Eastern Virginia Medical School, Norfolk, VA, USA. Electronic address: SanforLD@evms.edu. 3. Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong Special Administrative Region. 4. National Institute on Drug Dependence, Peking University Sixth Hospital, Peking University, Beijing, China. 5. Sleep Medicine Center, Department of Respiratory and Critical Care Medicine, Mental Health Center, Translational Neuroscience Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China. Electronic address: 2372564613@qq.com.
Abstract
BACKGROUND: Nightmares are a highly prevalent and distressing feature of post-traumatic stress disorder (PTSD). Previous studies have reached mixed conclusions regarding the effects of prazosin on nightmares, sleep quality, and overall PTSD symptoms in patients with PTSD. METHODS: MEDLINE, EMBASE, all EBM databases, PsycIFNO, and CINAHL were systematically searched from inception date to October 2018 for randomized clinical trials that included reporting of nightmares, sleep quality or overall PTSD symptoms. The analysis included data from eight trials involving 286 PTSD patients in the prazosin group and 289 PTSD patients in the placebo group. RESULTS: In our meta-analysis, prazosin resulted in a statistically significant improvement in nightmares (standardized mean difference (SMD) = -1.13, 95% confidence interval (CI) = -1.91 to -0.36), but was not more beneficial than placebo for overall PTSD symptoms (SMD = -0.45, 95% CI = -0.95 to 0.05) and sleep quality (SMD = -0.44, 95% CI = -1.44 to 0.55). In terms of acceptability, there was no significant difference between the prazosin group and the placebo group with respect to discontinuation for all causes (odds ratio (OR) = 1.00, 95% CI = 0.62-1.62). In conclusion, the use of prazosin was associated with an improvement of nightmare symptoms. CONCLUSION: Our findings indicate that additional studies are needed before considering downgrading the use of prazosin in the treatment of nightmares in patients with PTSD.
BACKGROUND: Nightmares are a highly prevalent and distressing feature of post-traumatic stress disorder (PTSD). Previous studies have reached mixed conclusions regarding the effects of prazosin on nightmares, sleep quality, and overall PTSD symptoms in patients with PTSD. METHODS: MEDLINE, EMBASE, all EBM databases, PsycIFNO, and CINAHL were systematically searched from inception date to October 2018 for randomized clinical trials that included reporting of nightmares, sleep quality or overall PTSD symptoms. The analysis included data from eight trials involving 286 PTSDpatients in the prazosin group and 289 PTSDpatients in the placebo group. RESULTS: In our meta-analysis, prazosin resulted in a statistically significant improvement in nightmares (standardized mean difference (SMD) = -1.13, 95% confidence interval (CI) = -1.91 to -0.36), but was not more beneficial than placebo for overall PTSD symptoms (SMD = -0.45, 95% CI = -0.95 to 0.05) and sleep quality (SMD = -0.44, 95% CI = -1.44 to 0.55). In terms of acceptability, there was no significant difference between the prazosin group and the placebo group with respect to discontinuation for all causes (odds ratio (OR) = 1.00, 95% CI = 0.62-1.62). In conclusion, the use of prazosin was associated with an improvement of nightmare symptoms. CONCLUSION: Our findings indicate that additional studies are needed before considering downgrading the use of prazosin in the treatment of nightmares in patients with PTSD.
Authors: R Nisha Aurora; Rochelle S Zak; Sanford H Auerbach; Kenneth R Casey; Susmita Chowdhuri; Anoop Karippot; Rama K Maganti; Kannan Ramar; David A Kristo; Sabin R Bista; Carin I Lamm; Timothy I Morgenthaler Journal: J Clin Sleep Med Date: 2010-08-15 Impact factor: 4.062
Authors: S J Wilson; D J Nutt; C Alford; S V Argyropoulos; D S Baldwin; A N Bateson; T C Britton; C Crowe; D-J Dijk; C A Espie; P Gringras; G Hajak; C Idzikowski; A D Krystal; J R Nash; H Selsick; A L Sharpley; A G Wade Journal: J Psychopharmacol Date: 2010-09-02 Impact factor: 4.153
Authors: Davit Khachatryan; Dianne Groll; Linda Booij; Amir A Sepehry; Christian G Schütz Journal: Gen Hosp Psychiatry Date: 2015-11-01 Impact factor: 3.238
Authors: Fletcher B Taylor; Patti Martin; Charles Thompson; Judi Williams; Thomas A Mellman; Christopher Gross; Elaine R Peskind; Murray A Raskind Journal: Biol Psychiatry Date: 2007-09-14 Impact factor: 13.382
Authors: Chad E Shenk; Brooks Keeshin; Heather E Bensman; Anneke E Olson; Brian Allen Journal: Pharmacol Biochem Behav Date: 2021-11-10 Impact factor: 3.533
Authors: Claire Mallet; Christina F Chick; Redwan Maatoug; Philippe Fossati; Alain Brunet; Bruno Millet Journal: J Clin Sleep Med Date: 2022-07-01 Impact factor: 4.324